EVELO BIOSCIENCES INC (EVLO)

US2997342025 - Common Stock

0.3165  -0.05 (-14.46%)

After market: 0.3159 0 (-0.19%)

Fundamental Rating

0

EVLO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 592 industry peers in the Biotechnology industry. EVLO may be in some trouble as it scores bad on both profitability and health. EVLO is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

In the past year EVLO has reported negative net income.
EVLO had a negative operating cash flow in the past year.
In the past 5 years EVLO always reported negative net income.
In the past 5 years EVLO always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -399.71%, EVLO is not doing good in the industry: 97.84% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -399.71%
ROE N/A
ROIC N/A
ROA(3y)-140.08%
ROA(5y)-110.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EVLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, EVLO has more shares outstanding
EVLO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, EVLO has a worse debt to assets ratio.

2.2 Solvency

EVLO has an Altman-Z score of -53.01. This is a bad value and indicates that EVLO is not financially healthy and even has some risk of bankruptcy.
EVLO's Altman-Z score of -53.01 is on the low side compared to the rest of the industry. EVLO is outperformed by 97.01% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -53.01
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 0.47 indicates that EVLO may have some problems paying its short term obligations.
EVLO has a Current ratio of 0.47. This is amonst the worse of the industry: EVLO underperforms 95.02% of its industry peers.
EVLO has a Quick Ratio of 0.47. This is a bad value and indicates that EVLO is not financially healthy enough and could expect problems in meeting its short term obligations.
EVLO has a Quick ratio of 0.47. This is amonst the worse of the industry: EVLO underperforms 94.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.47

1

3. Growth

3.1 Past

The earnings per share for EVLO have decreased strongly by -131.81% in the last year.
EPS 1Y (TTM)-131.81%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q87.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 14.98% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.07%
EPS Next 2Y38.62%
EPS Next 3Y24.47%
EPS Next 5Y14.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVLO. In the last year negative earnings were reported.
Also next year EVLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as EVLO's earnings are expected to grow with 24.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y24.47%

0

5. Dividend

5.1 Amount

EVLO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

EVELO BIOSCIENCES INC

NASDAQ:EVLO (12/11/2023, 7:00:02 PM)

After market: 0.3159 0 (-0.19%)

0.3165

-0.05 (-14.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.99M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -399.71%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.47
Quick Ratio 0.47
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-131.81%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y85.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y